B+
Bull case
30%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
NVCR
NovoCureDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The constructive case is that Novocure now has multiple concrete proof points rather than a pure platform story: Japan reimbursement approval for Optune Lua opens a new covered market for NSCLC [#PR-2026-03-02], PANOVA-4 reported statistically significant disease-control improvement in metastatic pancreatic cancer [#PR-2026-03-26], and management's 2026 guide implies incremental contribution from newer indications and products [#PR-2026-02-26-FY]. With the stock still near $12.67 versus a packet median target near $25.93, the setup can work if upcoming milestones convert into visible patient and revenue traction.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.0.
What can break
April 30, 2026 earnings could fail to show convincing early revenue contribution from Optune Pax and Optune Lua.
Momentum
70
Value
37
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.50 · Bull $19.00 · Bear $8.50Analysis 2026-04-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $27.14
Why
Momentum70 · Δ7d +17.0
Value37 · Δ7d -0.0
Sentiment53 · Δ7d +8.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.0.
Contradictions & invalidation
- • April 30, 2026 earnings could fail to show convincing early revenue contribution from Optune Pax and Optune Lua.
- • Clinical readout risk remains high around TRIDENT despite management's Q2 2026 timing.
- • The bearish case is that forward visibility is still limited and the thesis remains milestone-dependent.
Catalyst clock
2026-04-30
Q1 2026 results on April 30 can validate early Optune Pax/Lua revenue ramp and active-patient trajectory
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendImproving
Δ7d
+17.0
Δ21d
+3.6
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
53
62% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+4.6
Why this grade
Composite grade D. Momentum 70.1 / Value 36.6 / Sentiment 53.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.04B
Beta
0.72
Shares Out
116.45M
P/E (TTM) · Derived
-14.3
P/S (TTM)
2.40
P/FCF (TTM) · Derived
-78.33
Rev YoY
+15.6%
EPS YoY
-62.5%
Gross Margin
+76.1%
Op Margin
-22.1%
Net Debt
-$209.16M
Current Ratio
2.89
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data